

IN THE CLAIMS

Claims 1-10 (canceled).

11. (Currently amended) A method for the production of an influenza virus vaccine for nasal or oral administration comprising combining an inactivated influenza virus with aluminum in a composition suitable for nasal or oral administration, wherein the composition is free of media and egg proteins.

12. (Previously presented) The method of claim 11, wherein the inactivated influenza virus is obtained from an infected cell culture.

13. (Currently amended) The method of ~~claims~~ claim 12, wherein the infected cell culture is incubated in a serum- and protein-free medium.

14. (Previously presented) The method of claim 11, wherein the inactivated influenza virus is subjected to purification after its inactivation.

15. (Previously amended) A method for the production of an influenza virus vaccine that is formulated for nasal or oral administration, wherein the method comprises combining influenza virus antigen obtained from a mammalian cell culture comprising protein-free media with an aluminum salt in a composition suitable for nasal or oral administration, wherein the composition is free of media and egg proteins.

16. (New) The method according to claim 15, wherein aluminum salt is aluminum hydroxide or aluminum phosphate.